Leepu Biosciences-B (02157) released its six-month performance as of June 30, 2024, with revenue of 0.133 billion...
Intelligent Finance APP News, Leepu Biosciences-B (02157) released its six-month performance as of June 30, 2024, with revenue of 0.133 billion yuan (RMB, the same below), a year-on-year decrease of 13.2%; the loss attributable to owners of the company expanded by 35.6% to 0.192 billion yuan; basic loss per share is 0.12 yuan.
In the six months ended June 30, 2024, the decrease in revenue was due to the recognition of external authorization licensing revenue of approximately RMB 0.1095 billion (including one-time prepayment) for CMG901 under the license agreement in the same period of 2023, while the revenue recognized for milestone payments and technology transfer services during the reporting period was approximately RMB 20.7 million. Part of it was offset by the doubled revenue from the sale of Puyuheng (Puterli Monoclonal Antibody Injection) and the confirmed revenue of approximately RMB 17.8 million from providing CDMO services (six months ended June 30, 2023: zero).
